IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Patent Application of Attv Dkt. 117-358 C# M# VALLANCE et al C/A.U. 1632 2 6 2004 Serial No. 09/889,733 Examiner: S.D. Priebe Filed: September 14, 200 Date: February 26, 2004 RECEIVED DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED) Title: MAR 0 9 2004 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: **RESPONSE TO RESTRICTION REQUIREMENT** This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon. Correspondence Address Indication Form Attached. Fees are attached as calculated below: Total effective claims after amendment minus highest number previously paid for (at least 20) =\$ 18.00 \$ 0.00 Independent claims after amendment minus highest number 0.00 previously paid for 12 \$ 86.00 \$ (at least 3) =0 Х \$ 0.00 If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper) Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ 1.480.0 0.00 \$ Terminal disclaimer enclosed, add \$ 110.00 First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00) \$ 0.00 Please enter the previously unentered , filed Submission attached Subtotal 1480.00 \$ If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00 Applicant claims "small entity" status. 

Statement filed herewith \$ Rule 56 Information Disclosure Statement Filing Fee (\$180.00) 0.00 Assignment Recording Fee (\$40.00) 0.00 Other: INFORMATION DISCLOSURE STATEMENT; PTO FORM-1449 AND REFERENCES TOTAL FEE ENCLOSED \$ The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

GRT:ap

NIXON & VANDERHYE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of

VALLANCE et al.

Appln. No. 09/889,733

Filed: September 14, 2001

RECEIVED Confirmation No.: 9

MAR 0 9 2004 Atty. Ref.: 117-358

Confirmation No.: 9066

Group Art Unit: 1632

Examiner: S.D. Priebe

FOR: HUMAN DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (as amended)

## RESPONSE TO RESTRICTION REQUIREMENT

February 26, 2004

U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the pending Office Action (Paper No. 092203) mailed September 26, 2003, entry and consideration of the following amendments and remarks are respectfully requested.

Amended portions of the **specification** are presented on page 2.

A priority statement is added.

The Abstract of the Disclosure is attached.

The **claims** are presented on pages 3-9.

Claims 46, 48-52, 64 and 66-67 are amended.

Claims 54-63 and 68-70 are canceled without prejudice or disclaimer.

Claims 71-82 are added.

Remarks begin on page 10.

03/02/2004 MMEKONEN 00000010 09889733

01 FC:1254

1480.00 QP